Benefit — ICH E6(R3) quality-management
What Snapshot-grade E6(R3) evidence actually saves you
ICH E6(R3) is the frame FDA BIMO, EMA GCP inspectors, MHRA inspectors, IRB continuing-review boards, and DSMB chairs apply when asking "what's your sponsor quality-management for the trial AI?" A dated independent record changes the answer.
The three moments where it matters
- GCP inspection (FDA BIMO / EMA GCP / MHRA / PMDA). Inspector applies E6(R3) proportionality frame to AI-in-trial. Independent monitoring evidence directly answers the sponsor-quality question.
- DSMB pre-read. Chair reviews AI-driven eligibility monitoring against E6(R3) risk-based-monitoring frame. Independent record shortens the review path.
- IRB continuing-review. Board applies E6(R3) essential-documents duty to AI-decision records. Retention + monitoring on file supports continuing approval without site-suspension risk.
Dollar frame
GCP-inspection finding cost: a serious sponsor-quality finding on AI-in-trial can drive $1M-$10M in remediation + amended-submission + re-inspection cycle cost.
Site-suspension cost: per-site recruitment-restart cost typically $250K-$1M. Compounding across a multi-site Phase III trial adds up quickly.
Preventive discipline cost: $499 for the risk-based-monitoring evidence + essential-documents scope confirmation.
Who at your org cares
- Chief Quality Officer — sponsor QMS integrity
- VP Regulatory Affairs — GCP-inspection stance
- Head of Clinical Operations — site + DSMB + IRB relationships
- Chief Medical Officer — medical-oversight defensibility
What "having it" looks like
Green: Snapshot on file. Risk-based-monitoring evidence proportionate to the AI-eligibility-decision risk. Inspection close-out on merits.
Red: No independent record. Inspector's follow-up probes surface the sponsor-quality gap. Findings compound.
$499. 3 business days.
Independent-verifier record aligned to the E6(R3) proportionality frame. On your sponsor's actual AI surface.
Buy $499